JP Morgan 2026: Bristol Myers Squibb Focuses on the Next Decade

According to Bristol Myers Squibb board chair and CEO Christopher Boerner, PhD, the company’s future will be built upon a wider spread of drugs and products than previous years.

The executive spoke at the 44^th annual 2026 JP Morgan Healthcare Conference in San Francisco early on Monday, January 12. After presenting details about the company’s current financial state and its upcoming pipeline, Boerner had a brief conversation with Chris Schott of JP Morgan.

During the presentation portion, Boerner discussed how Bristol Myers is focused on building a solid financial foundation to lead the company into the 2030s. He presented a multi-year plan during which he says the company has a significant number of shots on goal for developing potential blockbuster drugs.

He listed the following drugs as assets that each have multi-billion dollar potential:

• Cobenfy – neuroscience
• Milvexian – cardiovascular
• Admilparant – immunology
• Pumitamig – oncology
• Iberdomide & Mezigdomide – oncology

Beyond that, he also detailed the high number of potential drugs that have significant data expected to come in within the next few years. Bristole Myers has 13 drugs that expect to have NME registrational data between 2026 to 2028. LCM pivotal data is expected for 14 indications during the same time period.

The presentation continued with Boerner discussing ways that capital has been deployed, which includes strategic business development deals with the following companies:

• Biontech
• Philochem
• Orbital
• Systimmune
• Immunology NewCo
• RayzeBio
• Mirati Therapeutics
• Karuna Therapeutics

Bristol Myers will also continue its trend of making dividend payments, which it has done consecutively for the past 94 years. In the upcoming year, it plans to prioritize its investments based on what it continues to be the highest opportunity assets and R&D.

The key theme throughout Boerner’s presentation is that company plans to focus heavily on its growth portfolio in the coming years.

During the second half of the JP Morgan presentation, Boerner discussed his tenure as CEO of Bristol Myers with Schott. When asked about what’s gone better than he expected during his time in the executive’s office, Boerner answered with growth. He also discussed how he and the team at Bristol Myers have been successful at taking costs of out the system.

When asked about elements that still need improvement, Boerner stated that there had been some setbacks on the development side, but that he also believes that the current team is the right team to drive execution.

While much of the presentation focused on the years to come, Boerner also discussed the plans for 2026. These include a focus on commercial execution, prosecuting the pipeline, and maintaining financial discipline.

In regard to the upcoming patent cliff, Boerner said that he’s much more confident now than he was 2-3 years ago. He cited the six new medicines in development for 2026 as the reason why his confidence is higher.

The same morning of the JP Morgan presentation, Bristol Myers announced positive topline results from SCOUT-HCM, a phase 3 trial evaluating Camzyos, a cardiac myosin inhibitor being studied for its effectiveness treating obstructive hypertrophic cardiomyopathy in adolescent patients.²

In a press release, Bristol Myers Squibb’s chief medical officer and head of development Cristian Massacesi, MD, said, “Adolescent oHCM is a serious, rare disease associated with substantial morbidity and mortality. The SCOUT-HCM topline results highlight the potential for Camzyos to be the first cardiac myosin inhibitor for adolescent patients with oHCM. Camzyos has redefined the treatment paradigm for symptomatic oHCM in adults, with over 20,000 patients started in the U.S. alone, and we look forward to the potential opportunity to transform clinical care in the adolescent patient population.”

In the same press release, principal investigator and chief of the division of cardiology at the Children’s Hostpial of Philadelphia Joseph Rossano, MD, said, “The SCOUT-HCM study is important for patients and the field of pediatric cardiology, being one of the very few pediatric cardiology randomized and placebo-controlled clinical trials that has generated positive Phase 3 results. Treatment options for adolescents with oHCM are currently limited to medical symptom management or invasive surgery. As a clinician who has cared for patients in this field for decades, I am very excited about the potential opportunity that a therapy like this could hold for the patient population if approved by the FDA."

Sources

1. 44th Annual J.P. Morgan Healthcare Conference. Bristol Myers Squibb. January 12, 2026. https://bristolmyers2016ir.q4web.com/iframes/events-and-presentations/event-details/2026/44th-Annual-JP-Morgan-Healthcare-Conference-2026-C5dJazizl2/default.aspx
2. Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). Bristol Myers Squibb. January 12, 2026. https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Phase-3-SCOUT-HCM-Trial-Evaluating-Camzyos-mavacamten-in-Adolescents-with-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-oHCM/default.aspx